Tagged Articles

Janssen Pharmaceuticals 238 articles

J&J settles lawsuit alleging Risperdal caused boy to grow breasts

Johnson & Johnson and its unit Janssen Pharmaceuticals have agreed to settle a lawsuit brought by a Mississippi family that claimed the companies’ antipsychotic drug Risperdal caused their son to develop breasts, a disfiguring condition known as gynecomastia, according to Law360. The announcement came just days before the case was slated to go to trial in Pennsylvania state court. The settlement follows a Superior Court ruling in January during which a global order barring punitive damages on gynecomastia claims with Risperdal in the Philadelphia County Court of Common Pleas was upended. Suddenly faced with the potential of  punitive damages, Johnson ... Read More

Two Risperdal cases allowed to seek punitive damages

Two boys can seek punitive damages from Johnson & Johnson’s Janssen Pharmaceuticals on their claims that the company failed to warn them that its antipsychotic Risperdal could cause them to develop female-like breasts, a Pennsylvania judge ruled. The cases were a part of a mass tort program in the Philadelphia County Court of Common Pleas, where about 6,700 cases are pending. In May 2014, Judge New had issued a global order for the Risperdal mass tort program that because of Janssen’s business ties to New Jersey, the company could fall under that state’s law, which protects drug companies against punitive damages ... Read More

Judge urges superior court to uphold $70 million Risperdal verdict

Philadelphia Court of Common Pleas Judge Paula Patrick, who oversaw the 2016 trial that ended with a $70 million award for a child who claimed the antipsychotic drug Risperdal disfigured him, urged the Pennsylvania Superior Court to uphold the verdict saying the multimillion-dollar award was within the jury’s discretion. “Upon consideration of the evidence presented at the trial and the damages sustained by the plaintiffs, this court believes that the jury’s findings should not be disturbed,” Judge Patrick said. Johnson & Johnson subsidiary Janssen Pharmaceuticals appealed the verdict to the Superior Court, arguing that the verdict was excessive. It was ... Read More

Invokana sales fall after amputation warnings

When the Food and Drug Administration (FDA) announced in March 2017 that it was requiring Johnson & Johnson and its subsidiary Janssen Pharmaceuticals to add a boxed warning – the strongest warning required by the FDA – to the labels of its type 2 diabetes medication Invokana regarding an increased risk of amputations in users, some doctors and hospital-affiliated medical groups rushed to take patients off the drug. Amputation is already a risk for diabetics. Why worsen the odds? The FDA Safety Communication informed consumers that leg and foot amputations occurred about twice as often in patients taking Invokana than ... Read More

Lawsuits claim diabetes drug Invokana caused leg amputations

Two men have filed lawsuits in the Superior Court of New Jersey Law Division in Middlesex County against Johnson & Johnson unit Janssen Pharmaceuticals alleging the company’s type 2 diabetes drug Invokana caused them to have their legs amputated. Robert E. Shook, 60, of Alabama claims that he had to undergo below-knee, left foot and left leg amputations after taking Invokana. Michael A. Wilkinson, 53, of Iowa, alleges he had to undergo right leg and below-knee amputations after using the drug. Both men have since stopped taking Invokana. The lawsuits claim that Janssen failed to warn doctors and patients that ... Read More

Risperdal case sent back to determine if punitive damages are warranted

The Pennsylvania Superior Court sent a case involving Risperdal side effects back to trial court to decide whether a new trial on punitive damages is warranted. The case was the third bellwether to go to trial from a mass tort program in the Philadelphia County Court of Common Pleas alleging Johnson & Johnson and its subsidiary Janssen Pharmaceuticals failed to warn that its antipsychotic Risperdal could cause adolescent boys to grow female-like breast tissue. The case is that of Nicholas Murray, a Maryland resident, who claimed he took Risperdal for five years as an adolescent, during which time he developed ... Read More

PA judges consider appeal on Risperdal statute of limitations

Johnson & Johnson’s Janssen Pharmaceuticals asked the Pennsylvania Supreme Court to deny an appeal on a recent decision to roll back the clock on when claims of abnormal beast growth in adolescent boys allegedly caused by the antipsychotic Risperdal began to expire. The justices are considering whether to hear an appeal of a ruling by the state’s Supreme Court that puts in jeopardy hundreds of lawsuits among the more than 6,600 currently pending in a mass tort program in Philadelphia County Court of Common Pleas. In November, the court ruled that plaintiffs should have known their breast growth was caused ... Read More

Appeals court rejects J&J’s bid to challenge expert in Risperdal side effects case

A Pennsylvania appeals court rejected Johnson & Johnson’s bid to challenge expert testimony in a trial over claims that its antipsychotic drug Risperdal caused a boy to grow female breasts, which resulted in a $1.75 million verdict against the drug company and its subsidiary Janssen Pharmaceuticals. The verdict was later reduced after a trial judge agreed that the plaintiff was bound by Maryland law, which limits noneconomic damages to $680,000. The three-judge Superior Court panel rejected Janssen’s arguments that plaintiffs expert Dr. Francesco DeLuca had improperly relied on an 8-year-old photograph of plaintiff Nicholas Murry to determine he had gynecomastia, ... Read More

Xarelto mass tort program in PA continues to grow

The Xarelto mass tort program in Philadelphia experienced the second-highest level of growth during 2017, jumping from 1,214 cases at the start of the year to 1,619 by year’s end, representing a 33 percent growth, according to court statistics. The only other mass tort program that grew more was that involving the antipsychotic Risperdal. Three Xarelto bellwether trials have already occurred in the federal multidistrict litigation (MDL) where another 20,000 lawsuits are currently pending. One case tried in Philadelphia resulted in a $27.8 million verdict for the plaintiff. The award was overturned and is currently on appeal to the Supreme ... Read More

Risperdal lawsuits in PA court nearly doubled in 2017

For the second year in a row, mass tort programs in Philadelphia have reached record highs, with litigation involving the antipsychotic drug Risperdal once again leading the pack. The total inventory of mass tort programs in the city jumped from 196 at the beginning of 2017 to 10,984 by year’s end, representing a 77 percent increase for the Complex Litigation Center’s overall inventory. Pharmaceutical cases saw the most growth in the court, starting the year at 5,601 cases and nearly doubling to 10,395 by Dec. 31, 2017 – a startling 85.5 percent increase. The vast majority of the growth is ... Read More